Advances in treatment of metastatic colorectal cancer with BRAF gene mutation / 中国综合临床

ABSTRACT

Objective V-raf murine sarcoma virus oncogene homologous gene B (BRAF) gene plays an important role in mitogen-activated protein kinase signaling pathway by encoding RAF family serine/ threonine protein kinase.Mutations in the BRAF gene can lead to tumorigenesis.About 10％ of metastatic colorectal cancers have BRAF gene mutations.The prognosis of this type of cancer is poor,with a median overall survival of 12 months.Recent studies have shown that FOLFOXIRI regimen combined with bevacizumab can be used as a first-line treatment.In addition,simultaneous targeting inhibition of multiple signaling pathways can bring survival benefits to these patients.